225 related articles for article (PubMed ID: 24740997)
1. A high-throughput fluorimetric assay for 2-hydroxyglutarate identifies Zaprinast as a glutaminase inhibitor.
Elhammali A; Ippolito JE; Collins L; Crowley J; Marasa J; Piwnica-Worms D
Cancer Discov; 2014 Jul; 4(7):828-39. PubMed ID: 24740997
[TBL] [Abstract][Full Text] [Related]
2. Treatment with a Small Molecule Mutant IDH1 Inhibitor Suppresses Tumorigenic Activity and Decreases Production of the Oncometabolite 2-Hydroxyglutarate in Human Chondrosarcoma Cells.
Li L; Paz AC; Wilky BA; Johnson B; Galoian K; Rosenberg A; Hu G; Tinoco G; Bodamer O; Trent JC
PLoS One; 2015; 10(9):e0133813. PubMed ID: 26368816
[TBL] [Abstract][Full Text] [Related]
3. (R)-2-Hydroxyglutarate Inhibits KDM5 Histone Lysine Demethylases to Drive Transformation in IDH-Mutant Cancers.
Gunn K; Myllykoski M; Cao JZ; Ahmed M; Huang B; Rouaisnel B; Diplas BH; Levitt MM; Looper R; Doench JG; Ligon KL; Kornblum HI; McBrayer SK; Yan H; Duy C; Godley LA; Koivunen P; Losman JA
Cancer Discov; 2023 Jun; 13(6):1478-1497. PubMed ID: 36847506
[TBL] [Abstract][Full Text] [Related]
4. Identification of additional IDH mutations associated with oncometabolite R(-)-2-hydroxyglutarate production.
Ward PS; Cross JR; Lu C; Weigert O; Abel-Wahab O; Levine RL; Weinstock DM; Sharp KA; Thompson CB
Oncogene; 2012 May; 31(19):2491-8. PubMed ID: 21996744
[TBL] [Abstract][Full Text] [Related]
5. IDH mutation impairs histone demethylation and results in a block to cell differentiation.
Lu C; Ward PS; Kapoor GS; Rohle D; Turcan S; Abdel-Wahab O; Edwards CR; Khanin R; Figueroa ME; Melnick A; Wellen KE; O'Rourke DM; Berger SL; Chan TA; Levine RL; Mellinghoff IK; Thompson CB
Nature; 2012 Feb; 483(7390):474-8. PubMed ID: 22343901
[TBL] [Abstract][Full Text] [Related]
6. The potential for isocitrate dehydrogenase mutations to produce 2-hydroxyglutarate depends on allele specificity and subcellular compartmentalization.
Ward PS; Lu C; Cross JR; Abdel-Wahab O; Levine RL; Schwartz GK; Thompson CB
J Biol Chem; 2013 Feb; 288(6):3804-15. PubMed ID: 23264629
[TBL] [Abstract][Full Text] [Related]
7. Hypoxia Induces Production of L-2-Hydroxyglutarate.
Intlekofer AM; Dematteo RG; Venneti S; Finley LW; Lu C; Judkins AR; Rustenburg AS; Grinaway PB; Chodera JD; Cross JR; Thompson CB
Cell Metab; 2015 Aug; 22(2):304-11. PubMed ID: 26212717
[TBL] [Abstract][Full Text] [Related]
8. Targeting Isocitrate Dehydrogenase Mutations in Cancer: Emerging Evidence and Diverging Strategies.
Waitkus MS; Yan H
Clin Cancer Res; 2021 Jan; 27(2):383-388. PubMed ID: 32883741
[TBL] [Abstract][Full Text] [Related]
9. Reductive carboxylation and 2-hydroxyglutarate formation by wild-type IDH2 in breast carcinoma cells.
Smolková K; Dvořák A; Zelenka J; Vítek L; Ježek P
Int J Biochem Cell Biol; 2015 Aug; 65():125-33. PubMed ID: 26007236
[TBL] [Abstract][Full Text] [Related]
10. Isocitrate dehydrogenase gene mutations and 2-hydroxyglutarate accumulation in esophageal squamous cell carcinoma.
Miyake K; Baba Y; Ishimoto T; Hiyoshi Y; Iwatsuki M; Miyamoto Y; Yoshida N; Watanabe M; Ogata Y; Nagayama M; Silsirivanit A; Kobayashi D; Araki N; Baba H
Med Oncol; 2018 Nov; 36(1):11. PubMed ID: 30506321
[TBL] [Abstract][Full Text] [Related]
11. Vascular-endothelial response to IDH1 mutant fibrosarcoma secretome and metabolite: implications on cancer microenvironment.
Mao MJ; Leonardi DE
Am J Cancer Res; 2019; 9(1):122-133. PubMed ID: 30755816
[TBL] [Abstract][Full Text] [Related]
12. Oncometabolite d-2HG alters T cell metabolism to impair CD8
Notarangelo G; Spinelli JB; Perez EM; Baker GJ; Kurmi K; Elia I; Stopka SA; Baquer G; Lin JR; Golby AJ; Joshi S; Baron HF; Drijvers JM; Georgiev P; Ringel AE; Zaganjor E; McBrayer SK; Sorger PK; Sharpe AH; Wucherpfennig KW; Santagata S; Agar NYR; Suvà ML; Haigis MC
Science; 2022 Sep; 377(6614):1519-1529. PubMed ID: 36173860
[TBL] [Abstract][Full Text] [Related]
13. 2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity.
Sulkowski PL; Corso CD; Robinson ND; Scanlon SE; Purshouse KR; Bai H; Liu Y; Sundaram RK; Hegan DC; Fons NR; Breuer GA; Song Y; Mishra-Gorur K; De Feyter HM; de Graaf RA; Surovtseva YV; Kachman M; Halene S; Günel M; Glazer PM; Bindra RS
Sci Transl Med; 2017 Feb; 9(375):. PubMed ID: 28148839
[TBL] [Abstract][Full Text] [Related]
14. Isocitrate dehydrogenase mutation as a therapeutic target in gliomas.
Han CH; Batchelor TT
Chin Clin Oncol; 2017 Jun; 6(3):33. PubMed ID: 28705010
[TBL] [Abstract][Full Text] [Related]
15. L-2-Hydroxyglutarate: an epigenetic modifier and putative oncometabolite in renal cancer.
Shim EH; Livi CB; Rakheja D; Tan J; Benson D; Parekh V; Kho EY; Ghosh AP; Kirkman R; Velu S; Dutta S; Chenna B; Rea SL; Mishur RJ; Li Q; Johnson-Pais TL; Guo L; Bae S; Wei S; Block K; Sudarshan S
Cancer Discov; 2014 Nov; 4(11):1290-8. PubMed ID: 25182153
[TBL] [Abstract][Full Text] [Related]
16. MYC-driven accumulation of 2-hydroxyglutarate is associated with breast cancer prognosis.
Terunuma A; Putluri N; Mishra P; Mathé EA; Dorsey TH; Yi M; Wallace TA; Issaq HJ; Zhou M; Killian JK; Stevenson HS; Karoly ED; Chan K; Samanta S; Prieto D; Hsu TY; Kurley SJ; Putluri V; Sonavane R; Edelman DC; Wulff J; Starks AM; Yang Y; Kittles RA; Yfantis HG; Lee DH; Ioffe OB; Schiff R; Stephens RM; Meltzer PS; Veenstra TD; Westbrook TF; Sreekumar A; Ambs S
J Clin Invest; 2014 Jan; 124(1):398-412. PubMed ID: 24316975
[TBL] [Abstract][Full Text] [Related]
17. Circulating oncometabolite D-2-hydroxyglutarate enantiomer is a surrogate marker of isocitrate dehydrogenase-mutated intrahepatic cholangiocarcinomas.
Delahousse J; Verlingue L; Broutin S; Legoupil C; Touat M; Doucet L; Ammari S; Lacroix L; Ducreux M; Scoazec JY; Malka D; Paci A; Hollebecque A
Eur J Cancer; 2018 Feb; 90():83-91. PubMed ID: 29274619
[TBL] [Abstract][Full Text] [Related]
18. Treatment Response Assessment in IDH-Mutant Glioma Patients by Noninvasive 3D Functional Spectroscopic Mapping of 2-Hydroxyglutarate.
Andronesi OC; Loebel F; Bogner W; Marjańska M; Vander Heiden MG; Iafrate AJ; Dietrich J; Batchelor TT; Gerstner ER; Kaelin WG; Chi AS; Rosen BR; Cahill DP
Clin Cancer Res; 2016 Apr; 22(7):1632-41. PubMed ID: 26534967
[TBL] [Abstract][Full Text] [Related]
19. Isocitrate dehydrogenase variants in cancer - Cellular consequences and therapeutic opportunities.
Liu S; Cadoux-Hudson T; Schofield CJ
Curr Opin Chem Biol; 2020 Aug; 57():122-134. PubMed ID: 32777735
[TBL] [Abstract][Full Text] [Related]
20. An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells.
Rohle D; Popovici-Muller J; Palaskas N; Turcan S; Grommes C; Campos C; Tsoi J; Clark O; Oldrini B; Komisopoulou E; Kunii K; Pedraza A; Schalm S; Silverman L; Miller A; Wang F; Yang H; Chen Y; Kernytsky A; Rosenblum MK; Liu W; Biller SA; Su SM; Brennan CW; Chan TA; Graeber TG; Yen KE; Mellinghoff IK
Science; 2013 May; 340(6132):626-30. PubMed ID: 23558169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
